Research programme: bleeding therapeutics (Ebola virus) - Fibreu Limited

Drug Profile

Research programme: bleeding therapeutics (Ebola virus) - Fibreu Limited

Latest Information Update: 10 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fibreu
  • Class Acute-phase proteins
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemorrhage

Most Recent Events

  • 10 Aug 2016 Preclinical trials in Haemorrhage in United Kingdom (unspecified route)
  • 12 Feb 2015 Research programme: bleeding therapeutics (Ebola virus) - Fibreu Limited receives Orphan Drug status for Haemorrhage in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top